https://obiterj.blogspot.com/2017/08/disclosure-survey-interim-results.html
Law and Lawyers: Disclosure Survey ~ Interim results - Disturbing results emerge
How should the legal system deal with your case if YOU were charged with a criminal offence? You would be certain to wish for a fair hear...
law and lawyersinterim resultsdisclosuresurveydisturbing
https://www.informa.com/media/press-releases-news/latest-news/interim-results-announced-on-26-july1/
Informa announces its Interim Results today
interim resultsinformaannouncestoday
https://jtcgroup.wistia.com/medias/lfb51pymos
JTC PLC Interim Results 2023
interim resultsjtcplc
https://rss.globenewswire.com/news-release/2023/05/09/2664530/0/en/Interim-Results-of-Study-That-Used-Non-invasive-Wireless-Patches-to-Monitor-Myoelectric-Activity-of-Crohn-s-Disease-Patients-in-Flare-and-Remission.html
Interim Results of Study That Used Non-invasive Wireless
MOUNTAIN VIEW, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- G-Tech Medical, a developer of non-invasive diagnostic solutions for patients with...
interim resultsnon invasivestudyusedwireless
https://mailarchive.ietf.org/arch/msg/idr/EykIONhjXEktD6P_dGK1CGGKJA4/
[Idr] Flow Specification Interim Results (June 7th, 2021)
Search IETF mail list archives
interim resultsidrflowspecificationjune
https://www.prnewswire.com/news-releases/innovent-announces-2025-interim-results-and-business-updates-302539881.html
Innovent Announces 2025 Interim Results and Business Updates
/PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes...
interim resultsinnoventannouncesbusinessupdates
https://markets.businessinsider.com/news/stocks/press-release-sinopec-fy2025-interim-results-1035061387
[Press Release] Sinopec FY2025 Interim Results | Markets Insider
EQS Newswire / 21/08/2025 / 21:00 UTC+8 Press release (For immediate release) Sinopec Announced 2025 Interim Results Recorded Net P...
press releaseinterim resultssinopecmarketsinsider
https://www.businesswire.com/news/home/20210712005251/en/Interim-Results-from-Phase-23-Studies-of-Molnupiravir-an-Investigational-Oral-Antiviral-Therapeutic-for-Mild-to-Moderate-COVID-19-Presented-at-the-European-Congress-of-Clinical-Microbiology-Infectious-Diseases-ECCMID
Interim Results from Phase 2/3 Studies of Molnupiravir, an Investigational Oral Antiviral...
Interim Results from Phase 2/3 Studies of Molnupiravir, Investigational Oral Antiviral Therapeutic for Mild to Moderate COVID-19, Presented at ECCMID
https://open.library.emory.edu/concern/publications/67e20022-f411-477d-96ed-cabca6033822
Interim results from an ongoing, open-label, single-arm trial of odevixibat in progressive familial...
Interim results from an ongoing, open-label, single-arm trial of odevixibat in progressive familial intrahepatic cholestasis